MRVI
Maravai LifeSciences Holdings Inc.
$4.38
-$0.02(-0.45%)
54
Overall
60
Value
70
Tech
34
Quality
Market Cap
$400.26M
Volume
5.11M
52W Range
$1.99 - $5.00
Target Price
$5.25
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $799.2M | $883.0M | $288.9M | $259.2M | $185.7M | ||
| Total Revenue | $799.2M | $883.0M | $288.9M | $259.2M | $185.7M | ||
| COST OF GOODS SOLD | |||||||
| Cost of Revenue | $140.6M | $169.0M | $148.7M | $150.9M | $151.8M | ||
| GROSS PROFIT | |||||||
| Gross Profit | $658.7M | $714.0M | $140.2M | $108.3M | $34.0M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $255.8M | $147.6M | $168.7M | $181.0M | $162.5M | ||
| Research & Development | $15.2M | $18.4M | $17.3M | $19.2M | $17.4M | ||
| Research Expense | $15.2M | $18.4M | $17.3M | $19.2M | $17.4M | ||
| Selling, General & Administrative | $100.1M | $129.3M | $151.4M | $161.8M | $145.1M | ||
| Selling & Marketing Expenses | $1.3M | $2.5M | $2.9M | $3.5M | -- | ||
| General & Administrative Expenses | $100.1M | $129.3M | $151.4M | $161.8M | $145.1M | ||
| Promotion & Advertising | $1.3M | -- | -- | -- | -- | ||
| Salaries & Wages | -- | $18.7M | $34.6M | $49.4M | $30.2M | ||
| Depreciation & Amortization | $140.6M | $7.6M | $12.9M | $20.9M | $23.6M | ||
| Depreciation & Amortization | $140.6M | $7.6M | $12.9M | $20.9M | $23.6M | ||
| Amortization | $140.6M | $307.9M | $353.4M | $27.5M | $28.0M | ||
| Other Operating Expenses | $-232.0K | -- | -- | $40.0K | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $554.6M | $574.2M | $-31.6M | $-235.6M | $-215.3M | ||
| EBITDA | $597.2M | $612.8M | $715.3M | $-154.0M | $-145.9M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $30.3M | $20.4M | $45.9M | $47.7M | $27.0M | ||
| Intinc | -- | $2.3M | $27.7M | $27.4M | $11.4M | ||
| Net Non-Operating Interest Income/Expense | $-30.3M | $-18.1M | $-18.2M | $-20.3M | $-15.6M | ||
| Other Income/Expense | $-11.5M | $3.1M | $-1.9M | $3.5M | $4.4M | ||
| Other Special Charges | $279.0K | $-566.0K | $-1.3M | $-5.5M | $-4.2M | ||
| SPECIAL ITEMS | |||||||
| Restructring And Mn A Income | -- | -- | $6.5M | $-1.2M | $17.8M | ||
| Special Income Charges | -- | $-4.1M | $-6.5M | $1.2M | $-17.8M | ||
| Impairment of Capital Assets | -- | -- | -- | $166.2M | $1.2M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $561.0M | $571.9M | $663.6M | $-213.8M | $-208.0M | ||
| Pre-Tax Income | $530.8M | $551.5M | $617.7M | $-261.5M | $-235.0M | ||
| INCOME TAX | |||||||
| Tax Provision | $61.5M | $60.8M | $756.1M | $-1.9M | $-4.2M | ||
| NET INCOME | |||||||
| Net Income | $182.0M | $220.2M | $-119.0M | $-144.8M | $-130.8M | ||
| Net Income (Continuing Operations) | $182.0M | $490.7M | $-138.4M | $-259.6M | $-230.8M | ||
| Net Income (Discontinued Operations) | $182.0M | $220.2M | $-119.0M | $-144.8M | $-130.8M | ||
| Net Income (Common Stockholders) | $182.0M | $220.2M | $-119.0M | $-144.8M | $-130.8M | ||
| Normalized Income | -- | -- | -- | -- | $-218.7M | ||
| TOTALS | |||||||
| Total Expenses | $396.4M | $316.6M | $317.4M | $331.9M | $314.3M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $114.8M | $131.5M | $131.9M | $137.9M | $144.4M | ||
| Average Shares Outstanding (Diluted) | $257.8M | $255.3M | $131.9M | $137.9M | $144.4M | ||
| Shares Outstanding | $255.2M | $250.9M | $251.4M | $254.3M | $257.1M | ||
| Basic EPS | $1.59 | $1.67 | $-0.90 | $-1.05 | $-0.90 | ||
| Basic EPS (Continuing Operations) | $1.59 | $1.67 | $-0.90 | $-1.05 | $-0.90 | ||
| Diluted EPS | $1.56 | $1.67 | $-0.90 | $-1.05 | $-0.90 | ||
| Diluted EPS (Continuing Operations) | $1.56 | $1.67 | $-0.90 | $-1.05 | $-0.90 | ||
| OTHER METRICS | |||||||
| Acquisition Expense | $1.5M | $2.4M | $4.4M | $1.7M | $1.3M | ||
| Gain On Sale Of Business | $11.2M | -- | -- | -- | -- | ||
| Insurance And Claims | -- | -- | -- | $40.0K | -- | ||
| Loss And Loss Adjustment Expected Incurred | -- | -- | $-668.9M | -- | -- | ||
| Minority Interests | $-287.2M | $-270.5M | $19.3M | $114.8M | $100.0M | ||
| Other Gand A | $100.1M | $129.3M | $151.4M | $161.8M | $145.1M | ||
| Write Down | -- | $4.1M | -- | -- | -- | ||
| Restruct | -- | -- | $6.5M | $-1.2M | $17.8M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MRVI | $4.38 | -0.5% | 5.11M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Maravai LifeSciences Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW